Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
Authors:
Open Access
- 29 June 2022
- journal article
- research article
- Published by Elsevier in New Biotechnology
- Vol. 71, 21-29
Abstract
No abstract availableKeywords
Funding Information
- Lung Cancer Research Foundation
- Bristol-Myers Squibb
- Cancerfonden (20 1147 PjF)
- Merck
- Vetenskapsrådet
- Akademiska Sjukhuset
- Roche
This publication has 52 references indexed in Scilit:
- EpiHealth: a large population-based cohort study for investigation of gene–lifestyle interactions in the pathogenesis of common diseasesEuropean Journal of Epidemiology, 2013
- MiR‐17/106b seed family regulates p21 in Hodgkin's lymphomaThe Journal of Pathology, 2011
- Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphomaLeukemia & Lymphoma, 2011
- Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical CodeCancer Epidemiology, Biomarkers & Prevention, 2010
- Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of proteinLeukemia, 2008
- S100A11, an Dual Mediator for Growth Regulation of Human KeratinocytesMolecular Biology of the Cell, 2008
- Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndromeCancer, 2005
- Lost in Transcription: p21 Repression, Mechanisms, and ConsequencesCancer Research, 2005
- Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphomaInternational Journal Of Clinical Practice, 2004
- Signalling pathways of the TNF superfamily: a double-edged swordNature Reviews Immunology, 2003